跳至主要内容
临床试验/NCT01535417
NCT01535417已完成3 期

A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee

Green Cross Corporation0 个研究点目标入组 198 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
198
主要终点
WOMAC change

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety of 'Shinbaro Capsule', a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
35 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age between 35 and 80
  • diagnosed with Knee OA based on criteria of ACR and showed ont through I ~ III of Kellgren Stage on radiography
  • wuffered constantly with Knee OA for more than 6 months prior to begining the study
  • scored more than 30 on total WOMAC scale

排除标准

  • had other comorbid orthopedic disease
  • had OA of index knee from significant trauma or surgery

研究组 & 干预措施

GCSB

Experimental

干预措施: Shinbaro Capsule (Drug)

Celebrex

Active Comparator

干预措施: Celebrex (Drug)

结局指标

主要结局

WOMAC change

时间窗: Baseline, 12 weeks

WOMAC change

次要结局

  • Adverse Events(12 weeks)
  • 100mm Pain VAS on walking(Baseline, 12 weeks)
  • PGART(12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验